Pharma & Healthcare
Global Targeted Drugs for Neurodegenerative Diseases Market Outlook, In‑Depth Analysis & Forecast to 2031
- Nov 04, 25
- ID: 560461
- Pages: 159
- Figures: 160
- Views: 1
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Targeted Drugs for Neurodegenerative Diseases market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Acadia Pharmaceuticals Inc.
Kyowa Kirin
Supernus Pharmaceuticals
UCB
Sumitomo Pharma
Biogen
Eisai Inc.
Eli Lilly
Green Valley
NOVARTIS
Bristol-Myers Squibb
Janssen
Sanofi
Roche
Neurocrine
Lundbeck
Teva
Segment by Type
Injection
Oral
Segment by Application
Parkinson's Disease (PD)
Alzheimer's Disease (AD)
Huntington's Disease (HD)
Tardive Dyskinesia (TD)
Multiple Sclerosis (MS)
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Targeted Drugs for Neurodegenerative Diseases study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Targeted Drugs for Neurodegenerative Diseases market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Acadia Pharmaceuticals Inc.
Kyowa Kirin
Supernus Pharmaceuticals
UCB
Sumitomo Pharma
Biogen
Eisai Inc.
Eli Lilly
Green Valley
NOVARTIS
Bristol-Myers Squibb
Janssen
Sanofi
Roche
Neurocrine
Lundbeck
Teva
Segment by Type
Injection
Oral
Segment by Application
Parkinson's Disease (PD)
Alzheimer's Disease (AD)
Huntington's Disease (HD)
Tardive Dyskinesia (TD)
Multiple Sclerosis (MS)
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Targeted Drugs for Neurodegenerative Diseases study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Targeted Drugs for Neurodegenerative Diseases: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Targeted Drugs for Neurodegenerative Diseases Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Injection
1.2.3 Oral
1.3 Market Segmentation by Application
1.3.1 Global Targeted Drugs for Neurodegenerative Diseases Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Parkinson's Disease (PD)
1.3.3 Alzheimer's Disease (AD)
1.3.4 Huntington's Disease (HD)
1.3.5 Tardive Dyskinesia (TD)
1.3.6 Multiple Sclerosis (MS)
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Targeted Drugs for Neurodegenerative Diseases Revenue Estimates and Forecasts 2020-2031
2.2 Global Targeted Drugs for Neurodegenerative Diseases Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Targeted Drugs for Neurodegenerative Diseases Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Targeted Drugs for Neurodegenerative Diseases Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Injection Market Size by Players
3.3.2 Oral Market Size by Players
3.4 Global Targeted Drugs for Neurodegenerative Diseases Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Targeted Drugs for Neurodegenerative Diseases Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Targeted Drugs for Neurodegenerative Diseases Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2020-2031)
6.4 North America Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Targeted Drugs for Neurodegenerative Diseases Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2020-2031)
7.4 Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2020-2031)
8.4 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2020-2031)
9.4 Central and South America Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Targeted Drugs for Neurodegenerative Diseases Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2020-2031)
10.4 Middle East and Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Acadia Pharmaceuticals Inc.
11.1.1 Acadia Pharmaceuticals Inc. Corporation Information
11.1.2 Acadia Pharmaceuticals Inc. Business Overview
11.1.3 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Product Features and Attributes
11.1.4 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2020-2025)
11.1.5 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Revenue by Product in 2024
11.1.6 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Revenue by Application in 2024
11.1.7 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Revenue by Geographic Area in 2024
11.1.8 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases SWOT Analysis
11.1.9 Acadia Pharmaceuticals Inc. Recent Developments
11.2 Kyowa Kirin
11.2.1 Kyowa Kirin Corporation Information
11.2.2 Kyowa Kirin Business Overview
11.2.3 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Product Features and Attributes
11.2.4 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2020-2025)
11.2.5 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Revenue by Product in 2024
11.2.6 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Revenue by Application in 2024
11.2.7 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Revenue by Geographic Area in 2024
11.2.8 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases SWOT Analysis
11.2.9 Kyowa Kirin Recent Developments
11.3 Supernus Pharmaceuticals
11.3.1 Supernus Pharmaceuticals Corporation Information
11.3.2 Supernus Pharmaceuticals Business Overview
11.3.3 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Product Features and Attributes
11.3.4 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2020-2025)
11.3.5 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Revenue by Product in 2024
11.3.6 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Revenue by Application in 2024
11.3.7 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Revenue by Geographic Area in 2024
11.3.8 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases SWOT Analysis
11.3.9 Supernus Pharmaceuticals Recent Developments
11.4 UCB
11.4.1 UCB Corporation Information
11.4.2 UCB Business Overview
11.4.3 UCB Targeted Drugs for Neurodegenerative Diseases Product Features and Attributes
11.4.4 UCB Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2020-2025)
11.4.5 UCB Targeted Drugs for Neurodegenerative Diseases Revenue by Product in 2024
11.4.6 UCB Targeted Drugs for Neurodegenerative Diseases Revenue by Application in 2024
11.4.7 UCB Targeted Drugs for Neurodegenerative Diseases Revenue by Geographic Area in 2024
11.4.8 UCB Targeted Drugs for Neurodegenerative Diseases SWOT Analysis
11.4.9 UCB Recent Developments
11.5 Sumitomo Pharma
11.5.1 Sumitomo Pharma Corporation Information
11.5.2 Sumitomo Pharma Business Overview
11.5.3 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Product Features and Attributes
11.5.4 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2020-2025)
11.5.5 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Revenue by Product in 2024
11.5.6 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Revenue by Application in 2024
11.5.7 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Revenue by Geographic Area in 2024
11.5.8 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases SWOT Analysis
11.5.9 Sumitomo Pharma Recent Developments
11.6 Biogen
11.6.1 Biogen Corporation Information
11.6.2 Biogen Business Overview
11.6.3 Biogen Targeted Drugs for Neurodegenerative Diseases Product Features and Attributes
11.6.4 Biogen Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2020-2025)
11.6.5 Biogen Recent Developments
11.7 Eisai Inc.
11.7.1 Eisai Inc. Corporation Information
11.7.2 Eisai Inc. Business Overview
11.7.3 Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Product Features and Attributes
11.7.4 Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2020-2025)
11.7.5 Eisai Inc. Recent Developments
11.8 Eli Lilly
11.8.1 Eli Lilly Corporation Information
11.8.2 Eli Lilly Business Overview
11.8.3 Eli Lilly Targeted Drugs for Neurodegenerative Diseases Product Features and Attributes
11.8.4 Eli Lilly Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2020-2025)
11.8.5 Eli Lilly Recent Developments
11.9 Green Valley
11.9.1 Green Valley Corporation Information
11.9.2 Green Valley Business Overview
11.9.3 Green Valley Targeted Drugs for Neurodegenerative Diseases Product Features and Attributes
11.9.4 Green Valley Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2020-2025)
11.9.5 Green Valley Recent Developments
11.10 NOVARTIS
11.10.1 NOVARTIS Corporation Information
11.10.2 NOVARTIS Business Overview
11.10.3 NOVARTIS Targeted Drugs for Neurodegenerative Diseases Product Features and Attributes
11.10.4 NOVARTIS Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Bristol-Myers Squibb
11.11.1 Bristol-Myers Squibb Corporation Information
11.11.2 Bristol-Myers Squibb Business Overview
11.11.3 Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Product Features and Attributes
11.11.4 Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2020-2025)
11.11.5 Bristol-Myers Squibb Recent Developments
11.12 Janssen
11.12.1 Janssen Corporation Information
11.12.2 Janssen Business Overview
11.12.3 Janssen Targeted Drugs for Neurodegenerative Diseases Product Features and Attributes
11.12.4 Janssen Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2020-2025)
11.12.5 Janssen Recent Developments
11.13 Sanofi
11.13.1 Sanofi Corporation Information
11.13.2 Sanofi Business Overview
11.13.3 Sanofi Targeted Drugs for Neurodegenerative Diseases Product Features and Attributes
11.13.4 Sanofi Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2020-2025)
11.13.5 Sanofi Recent Developments
11.14 Roche
11.14.1 Roche Corporation Information
11.14.2 Roche Business Overview
11.14.3 Roche Targeted Drugs for Neurodegenerative Diseases Product Features and Attributes
11.14.4 Roche Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2020-2025)
11.14.5 Roche Recent Developments
11.15 Neurocrine
11.15.1 Neurocrine Corporation Information
11.15.2 Neurocrine Business Overview
11.15.3 Neurocrine Targeted Drugs for Neurodegenerative Diseases Product Features and Attributes
11.15.4 Neurocrine Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2020-2025)
11.15.5 Neurocrine Recent Developments
11.16 Lundbeck
11.16.1 Lundbeck Corporation Information
11.16.2 Lundbeck Business Overview
11.16.3 Lundbeck Targeted Drugs for Neurodegenerative Diseases Product Features and Attributes
11.16.4 Lundbeck Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2020-2025)
11.16.5 Lundbeck Recent Developments
11.17 Teva
11.17.1 Teva Corporation Information
11.17.2 Teva Business Overview
11.17.3 Teva Targeted Drugs for Neurodegenerative Diseases Product Features and Attributes
11.17.4 Teva Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2020-2025)
11.17.5 Teva Recent Developments
12 Targeted Drugs for Neurodegenerative DiseasesIndustry Chain Analysis
12.1 Targeted Drugs for Neurodegenerative Diseases Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Targeted Drugs for Neurodegenerative Diseases Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Targeted Drugs for Neurodegenerative Diseases Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to Targeted Drugs for Neurodegenerative Diseases: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Targeted Drugs for Neurodegenerative Diseases Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Injection
1.2.3 Oral
1.3 Market Segmentation by Application
1.3.1 Global Targeted Drugs for Neurodegenerative Diseases Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Parkinson's Disease (PD)
1.3.3 Alzheimer's Disease (AD)
1.3.4 Huntington's Disease (HD)
1.3.5 Tardive Dyskinesia (TD)
1.3.6 Multiple Sclerosis (MS)
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Targeted Drugs for Neurodegenerative Diseases Revenue Estimates and Forecasts 2020-2031
2.2 Global Targeted Drugs for Neurodegenerative Diseases Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Targeted Drugs for Neurodegenerative Diseases Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Targeted Drugs for Neurodegenerative Diseases Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Injection Market Size by Players
3.3.2 Oral Market Size by Players
3.4 Global Targeted Drugs for Neurodegenerative Diseases Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Targeted Drugs for Neurodegenerative Diseases Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Targeted Drugs for Neurodegenerative Diseases Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2020-2031)
6.4 North America Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Targeted Drugs for Neurodegenerative Diseases Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2020-2031)
7.4 Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2020-2031)
8.4 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2020-2031)
9.4 Central and South America Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Targeted Drugs for Neurodegenerative Diseases Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2020-2031)
10.4 Middle East and Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Acadia Pharmaceuticals Inc.
11.1.1 Acadia Pharmaceuticals Inc. Corporation Information
11.1.2 Acadia Pharmaceuticals Inc. Business Overview
11.1.3 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Product Features and Attributes
11.1.4 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2020-2025)
11.1.5 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Revenue by Product in 2024
11.1.6 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Revenue by Application in 2024
11.1.7 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Revenue by Geographic Area in 2024
11.1.8 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases SWOT Analysis
11.1.9 Acadia Pharmaceuticals Inc. Recent Developments
11.2 Kyowa Kirin
11.2.1 Kyowa Kirin Corporation Information
11.2.2 Kyowa Kirin Business Overview
11.2.3 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Product Features and Attributes
11.2.4 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2020-2025)
11.2.5 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Revenue by Product in 2024
11.2.6 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Revenue by Application in 2024
11.2.7 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Revenue by Geographic Area in 2024
11.2.8 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases SWOT Analysis
11.2.9 Kyowa Kirin Recent Developments
11.3 Supernus Pharmaceuticals
11.3.1 Supernus Pharmaceuticals Corporation Information
11.3.2 Supernus Pharmaceuticals Business Overview
11.3.3 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Product Features and Attributes
11.3.4 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2020-2025)
11.3.5 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Revenue by Product in 2024
11.3.6 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Revenue by Application in 2024
11.3.7 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Revenue by Geographic Area in 2024
11.3.8 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases SWOT Analysis
11.3.9 Supernus Pharmaceuticals Recent Developments
11.4 UCB
11.4.1 UCB Corporation Information
11.4.2 UCB Business Overview
11.4.3 UCB Targeted Drugs for Neurodegenerative Diseases Product Features and Attributes
11.4.4 UCB Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2020-2025)
11.4.5 UCB Targeted Drugs for Neurodegenerative Diseases Revenue by Product in 2024
11.4.6 UCB Targeted Drugs for Neurodegenerative Diseases Revenue by Application in 2024
11.4.7 UCB Targeted Drugs for Neurodegenerative Diseases Revenue by Geographic Area in 2024
11.4.8 UCB Targeted Drugs for Neurodegenerative Diseases SWOT Analysis
11.4.9 UCB Recent Developments
11.5 Sumitomo Pharma
11.5.1 Sumitomo Pharma Corporation Information
11.5.2 Sumitomo Pharma Business Overview
11.5.3 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Product Features and Attributes
11.5.4 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2020-2025)
11.5.5 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Revenue by Product in 2024
11.5.6 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Revenue by Application in 2024
11.5.7 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Revenue by Geographic Area in 2024
11.5.8 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases SWOT Analysis
11.5.9 Sumitomo Pharma Recent Developments
11.6 Biogen
11.6.1 Biogen Corporation Information
11.6.2 Biogen Business Overview
11.6.3 Biogen Targeted Drugs for Neurodegenerative Diseases Product Features and Attributes
11.6.4 Biogen Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2020-2025)
11.6.5 Biogen Recent Developments
11.7 Eisai Inc.
11.7.1 Eisai Inc. Corporation Information
11.7.2 Eisai Inc. Business Overview
11.7.3 Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Product Features and Attributes
11.7.4 Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2020-2025)
11.7.5 Eisai Inc. Recent Developments
11.8 Eli Lilly
11.8.1 Eli Lilly Corporation Information
11.8.2 Eli Lilly Business Overview
11.8.3 Eli Lilly Targeted Drugs for Neurodegenerative Diseases Product Features and Attributes
11.8.4 Eli Lilly Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2020-2025)
11.8.5 Eli Lilly Recent Developments
11.9 Green Valley
11.9.1 Green Valley Corporation Information
11.9.2 Green Valley Business Overview
11.9.3 Green Valley Targeted Drugs for Neurodegenerative Diseases Product Features and Attributes
11.9.4 Green Valley Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2020-2025)
11.9.5 Green Valley Recent Developments
11.10 NOVARTIS
11.10.1 NOVARTIS Corporation Information
11.10.2 NOVARTIS Business Overview
11.10.3 NOVARTIS Targeted Drugs for Neurodegenerative Diseases Product Features and Attributes
11.10.4 NOVARTIS Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Bristol-Myers Squibb
11.11.1 Bristol-Myers Squibb Corporation Information
11.11.2 Bristol-Myers Squibb Business Overview
11.11.3 Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Product Features and Attributes
11.11.4 Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2020-2025)
11.11.5 Bristol-Myers Squibb Recent Developments
11.12 Janssen
11.12.1 Janssen Corporation Information
11.12.2 Janssen Business Overview
11.12.3 Janssen Targeted Drugs for Neurodegenerative Diseases Product Features and Attributes
11.12.4 Janssen Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2020-2025)
11.12.5 Janssen Recent Developments
11.13 Sanofi
11.13.1 Sanofi Corporation Information
11.13.2 Sanofi Business Overview
11.13.3 Sanofi Targeted Drugs for Neurodegenerative Diseases Product Features and Attributes
11.13.4 Sanofi Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2020-2025)
11.13.5 Sanofi Recent Developments
11.14 Roche
11.14.1 Roche Corporation Information
11.14.2 Roche Business Overview
11.14.3 Roche Targeted Drugs for Neurodegenerative Diseases Product Features and Attributes
11.14.4 Roche Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2020-2025)
11.14.5 Roche Recent Developments
11.15 Neurocrine
11.15.1 Neurocrine Corporation Information
11.15.2 Neurocrine Business Overview
11.15.3 Neurocrine Targeted Drugs for Neurodegenerative Diseases Product Features and Attributes
11.15.4 Neurocrine Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2020-2025)
11.15.5 Neurocrine Recent Developments
11.16 Lundbeck
11.16.1 Lundbeck Corporation Information
11.16.2 Lundbeck Business Overview
11.16.3 Lundbeck Targeted Drugs for Neurodegenerative Diseases Product Features and Attributes
11.16.4 Lundbeck Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2020-2025)
11.16.5 Lundbeck Recent Developments
11.17 Teva
11.17.1 Teva Corporation Information
11.17.2 Teva Business Overview
11.17.3 Teva Targeted Drugs for Neurodegenerative Diseases Product Features and Attributes
11.17.4 Teva Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2020-2025)
11.17.5 Teva Recent Developments
12 Targeted Drugs for Neurodegenerative DiseasesIndustry Chain Analysis
12.1 Targeted Drugs for Neurodegenerative Diseases Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Targeted Drugs for Neurodegenerative Diseases Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Targeted Drugs for Neurodegenerative Diseases Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Targeted Drugs for Neurodegenerative Diseases Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Targeted Drugs for Neurodegenerative Diseases Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Targeted Drugs for Neurodegenerative Diseases Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Targeted Drugs for Neurodegenerative Diseases Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Targeted Drugs for Neurodegenerative Diseases by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drugs for Neurodegenerative Diseases as of 2024)
Table 11. Global Targeted Drugs for Neurodegenerative Diseases Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Targeted Drugs for Neurodegenerative Diseases Companies Headquarters
Table 13. Global Targeted Drugs for Neurodegenerative Diseases Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Targeted Drugs for Neurodegenerative Diseases Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Targeted Drugs for Neurodegenerative Diseases Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Targeted Drugs for Neurodegenerative Diseases Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Targeted Drugs for Neurodegenerative Diseases Revenue by Application (2026-2031) & (US$ Million)
Table 21. Targeted Drugs for Neurodegenerative Diseases High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Targeted Drugs for Neurodegenerative Diseases Growth Accelerators and Market Barriers
Table 25. North America Targeted Drugs for Neurodegenerative Diseases Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Targeted Drugs for Neurodegenerative Diseases Growth Accelerators and Market Barriers
Table 27. Europe Targeted Drugs for Neurodegenerative Diseases Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Targeted Drugs for Neurodegenerative Diseases Investment Opportunities and Key Challenges
Table 31. Central and South America Targeted Drugs for Neurodegenerative Diseases Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Targeted Drugs for Neurodegenerative Diseases Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Targeted Drugs for Neurodegenerative Diseases Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Acadia Pharmaceuticals Inc. Corporation Information
Table 35. Acadia Pharmaceuticals Inc. Description and Major Businesses
Table 36. Acadia Pharmaceuticals Inc. Product Features and Attributes
Table 37. Acadia Pharmaceuticals Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Acadia Pharmaceuticals Inc. Revenue Proportion by Product in 2024
Table 39. Acadia Pharmaceuticals Inc. Revenue Proportion by Application in 2024
Table 40. Acadia Pharmaceuticals Inc. Revenue Proportion by Geographic Area in 2024
Table 41. Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases SWOT Analysis
Table 42. Acadia Pharmaceuticals Inc. Recent Developments
Table 43. Kyowa Kirin Corporation Information
Table 44. Kyowa Kirin Description and Major Businesses
Table 45. Kyowa Kirin Product Features and Attributes
Table 46. Kyowa Kirin Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Kyowa Kirin Revenue Proportion by Product in 2024
Table 48. Kyowa Kirin Revenue Proportion by Application in 2024
Table 49. Kyowa Kirin Revenue Proportion by Geographic Area in 2024
Table 50. Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases SWOT Analysis
Table 51. Kyowa Kirin Recent Developments
Table 52. Supernus Pharmaceuticals Corporation Information
Table 53. Supernus Pharmaceuticals Description and Major Businesses
Table 54. Supernus Pharmaceuticals Product Features and Attributes
Table 55. Supernus Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Supernus Pharmaceuticals Revenue Proportion by Product in 2024
Table 57. Supernus Pharmaceuticals Revenue Proportion by Application in 2024
Table 58. Supernus Pharmaceuticals Revenue Proportion by Geographic Area in 2024
Table 59. Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases SWOT Analysis
Table 60. Supernus Pharmaceuticals Recent Developments
Table 61. UCB Corporation Information
Table 62. UCB Description and Major Businesses
Table 63. UCB Product Features and Attributes
Table 64. UCB Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. UCB Revenue Proportion by Product in 2024
Table 66. UCB Revenue Proportion by Application in 2024
Table 67. UCB Revenue Proportion by Geographic Area in 2024
Table 68. UCB Targeted Drugs for Neurodegenerative Diseases SWOT Analysis
Table 69. UCB Recent Developments
Table 70. Sumitomo Pharma Corporation Information
Table 71. Sumitomo Pharma Description and Major Businesses
Table 72. Sumitomo Pharma Product Features and Attributes
Table 73. Sumitomo Pharma Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Sumitomo Pharma Revenue Proportion by Product in 2024
Table 75. Sumitomo Pharma Revenue Proportion by Application in 2024
Table 76. Sumitomo Pharma Revenue Proportion by Geographic Area in 2024
Table 77. Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases SWOT Analysis
Table 78. Sumitomo Pharma Recent Developments
Table 79. Biogen Corporation Information
Table 80. Biogen Description and Major Businesses
Table 81. Biogen Product Features and Attributes
Table 82. Biogen Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Biogen Recent Developments
Table 84. Eisai Inc. Corporation Information
Table 85. Eisai Inc. Description and Major Businesses
Table 86. Eisai Inc. Product Features and Attributes
Table 87. Eisai Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Eisai Inc. Recent Developments
Table 89. Eli Lilly Corporation Information
Table 90. Eli Lilly Description and Major Businesses
Table 91. Eli Lilly Product Features and Attributes
Table 92. Eli Lilly Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Eli Lilly Recent Developments
Table 94. Green Valley Corporation Information
Table 95. Green Valley Description and Major Businesses
Table 96. Green Valley Product Features and Attributes
Table 97. Green Valley Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Green Valley Recent Developments
Table 99. NOVARTIS Corporation Information
Table 100. NOVARTIS Description and Major Businesses
Table 101. NOVARTIS Product Features and Attributes
Table 102. NOVARTIS Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. NOVARTIS Recent Developments
Table 104. Bristol-Myers Squibb Corporation Information
Table 105. Bristol-Myers Squibb Description and Major Businesses
Table 106. Bristol-Myers Squibb Product Features and Attributes
Table 107. Bristol-Myers Squibb Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Bristol-Myers Squibb Recent Developments
Table 109. Janssen Corporation Information
Table 110. Janssen Description and Major Businesses
Table 111. Janssen Product Features and Attributes
Table 112. Janssen Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Janssen Recent Developments
Table 114. Sanofi Corporation Information
Table 115. Sanofi Description and Major Businesses
Table 116. Sanofi Product Features and Attributes
Table 117. Sanofi Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. Sanofi Recent Developments
Table 119. Roche Corporation Information
Table 120. Roche Description and Major Businesses
Table 121. Roche Product Features and Attributes
Table 122. Roche Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. Roche Recent Developments
Table 124. Neurocrine Corporation Information
Table 125. Neurocrine Description and Major Businesses
Table 126. Neurocrine Product Features and Attributes
Table 127. Neurocrine Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. Neurocrine Recent Developments
Table 129. Lundbeck Corporation Information
Table 130. Lundbeck Description and Major Businesses
Table 131. Lundbeck Product Features and Attributes
Table 132. Lundbeck Revenue (US$ Million) and Gross Margin (2020-2025)
Table 133. Lundbeck Recent Developments
Table 134. Teva Corporation Information
Table 135. Teva Description and Major Businesses
Table 136. Teva Product Features and Attributes
Table 137. Teva Revenue (US$ Million) and Gross Margin (2020-2025)
Table 138. Teva Recent Developments
Table 139. Raw Materials Key Suppliers
Table 140. Distributors List
Table 141. Market Trends and Market Evolution
Table 142. Market Drivers and Opportunities
Table 143. Market Challenges, Risks, and Restraints
Table 144. Research Programs/Design for This Report
Table 145. Key Data Information from Secondary Sources
Table 146. Key Data Information from Primary Sources
List of Figures
Figure 1. Targeted Drugs for Neurodegenerative Diseases Product Picture
Figure 2. Global Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Injection Product Picture
Figure 4. Oral Product Picture
Figure 5. Global Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Parkinson's Disease (PD)
Figure 7. Alzheimer's Disease (AD)
Figure 8. Huntington's Disease (HD)
Figure 9. Tardive Dyskinesia (TD)
Figure 10. Multiple Sclerosis (MS)
Figure 11. Targeted Drugs for Neurodegenerative Diseases Report Years Considered
Figure 12. Global Targeted Drugs for Neurodegenerative Diseases Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 14. Global Targeted Drugs for Neurodegenerative Diseases Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Region (2020-2031)
Figure 16. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share Ranking (2024)
Figure 17. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 18. Injection Revenue Market Share by Player in 2024
Figure 19. Oral Revenue Market Share by Player in 2024
Figure 20. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Type (2020-2031)
Figure 21. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Application (2020-2031)
Figure 22. North America Targeted Drugs for Neurodegenerative Diseases Revenue YoY (2020-2031) & (US$ Million)
Figure 23. North America Top 5 Players Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) in 2024
Figure 24. North America Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) by Type (2020 - 2031)
Figure 25. North America Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) by Application (2020-2031)
Figure 26. US Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 27. Canada Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 28. Mexico Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 29. Europe Targeted Drugs for Neurodegenerative Diseases Revenue YoY (2020-2031) & (US$ Million)
Figure 30. Europe Top 5 Players Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) in 2024
Figure 31. Europe Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) by Type (2020-2031)
Figure 32. Europe Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) by Application (2020-2031)
Figure 33. Germany Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 34. France Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 35. U.K. Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 36. Italy Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 37. Russia Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 38. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Revenue YoY (2020-2031) & (US$ Million)
Figure 39. Asia-Pacific Top 8 Players Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) in 2024
Figure 40. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) by Type (2020-2031)
Figure 41. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) by Application (2020-2031)
Figure 42. Indonesia Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 43. Japan Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 44. South Korea Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 45. Australia Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 46. India Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 47. Indonesia Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 48. Vietnam Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 49. Malaysia Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 50. Philippines Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 51. Singapore Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 52. Central and South America Targeted Drugs for Neurodegenerative Diseases Revenue YoY (2020-2031) & (US$ Million)
Figure 53. Central and South America Top 5 Players Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) in 2024
Figure 54. Central and South America Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) by Type (2020-2031)
Figure 55. Central and South America Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) by Application (2020-2031)
Figure 56. Brazil Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2025) & (US$ Million)
Figure 57. Argentina Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2025) & (US$ Million)
Figure 58. Middle East and Africa Targeted Drugs for Neurodegenerative Diseases Revenue YoY (2020-2031) & (US$ Million)
Figure 59. Middle East and Africa Top 5 Players Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) in 2024
Figure 60. South America Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) by Type (2020-2031)
Figure 61. Middle East and Africa Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) by Application (2020-2031)
Figure 62. GCC Countries Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2025) & (US$ Million)
Figure 63. Israel Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2025) & (US$ Million)
Figure 64. Egypt Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2025) & (US$ Million)
Figure 65. South Africa Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2025) & (US$ Million)
Figure 66. Targeted Drugs for Neurodegenerative Diseases Industry Chain Mapping
Figure 67. Channels of Distribution (Direct Vs Distribution)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
Table 1. Global Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Targeted Drugs for Neurodegenerative Diseases Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Targeted Drugs for Neurodegenerative Diseases Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Targeted Drugs for Neurodegenerative Diseases Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Targeted Drugs for Neurodegenerative Diseases Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Targeted Drugs for Neurodegenerative Diseases by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drugs for Neurodegenerative Diseases as of 2024)
Table 11. Global Targeted Drugs for Neurodegenerative Diseases Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Targeted Drugs for Neurodegenerative Diseases Companies Headquarters
Table 13. Global Targeted Drugs for Neurodegenerative Diseases Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Targeted Drugs for Neurodegenerative Diseases Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Targeted Drugs for Neurodegenerative Diseases Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Targeted Drugs for Neurodegenerative Diseases Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Targeted Drugs for Neurodegenerative Diseases Revenue by Application (2026-2031) & (US$ Million)
Table 21. Targeted Drugs for Neurodegenerative Diseases High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Targeted Drugs for Neurodegenerative Diseases Growth Accelerators and Market Barriers
Table 25. North America Targeted Drugs for Neurodegenerative Diseases Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Targeted Drugs for Neurodegenerative Diseases Growth Accelerators and Market Barriers
Table 27. Europe Targeted Drugs for Neurodegenerative Diseases Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Targeted Drugs for Neurodegenerative Diseases Investment Opportunities and Key Challenges
Table 31. Central and South America Targeted Drugs for Neurodegenerative Diseases Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Targeted Drugs for Neurodegenerative Diseases Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Targeted Drugs for Neurodegenerative Diseases Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Acadia Pharmaceuticals Inc. Corporation Information
Table 35. Acadia Pharmaceuticals Inc. Description and Major Businesses
Table 36. Acadia Pharmaceuticals Inc. Product Features and Attributes
Table 37. Acadia Pharmaceuticals Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Acadia Pharmaceuticals Inc. Revenue Proportion by Product in 2024
Table 39. Acadia Pharmaceuticals Inc. Revenue Proportion by Application in 2024
Table 40. Acadia Pharmaceuticals Inc. Revenue Proportion by Geographic Area in 2024
Table 41. Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases SWOT Analysis
Table 42. Acadia Pharmaceuticals Inc. Recent Developments
Table 43. Kyowa Kirin Corporation Information
Table 44. Kyowa Kirin Description and Major Businesses
Table 45. Kyowa Kirin Product Features and Attributes
Table 46. Kyowa Kirin Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Kyowa Kirin Revenue Proportion by Product in 2024
Table 48. Kyowa Kirin Revenue Proportion by Application in 2024
Table 49. Kyowa Kirin Revenue Proportion by Geographic Area in 2024
Table 50. Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases SWOT Analysis
Table 51. Kyowa Kirin Recent Developments
Table 52. Supernus Pharmaceuticals Corporation Information
Table 53. Supernus Pharmaceuticals Description and Major Businesses
Table 54. Supernus Pharmaceuticals Product Features and Attributes
Table 55. Supernus Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Supernus Pharmaceuticals Revenue Proportion by Product in 2024
Table 57. Supernus Pharmaceuticals Revenue Proportion by Application in 2024
Table 58. Supernus Pharmaceuticals Revenue Proportion by Geographic Area in 2024
Table 59. Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases SWOT Analysis
Table 60. Supernus Pharmaceuticals Recent Developments
Table 61. UCB Corporation Information
Table 62. UCB Description and Major Businesses
Table 63. UCB Product Features and Attributes
Table 64. UCB Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. UCB Revenue Proportion by Product in 2024
Table 66. UCB Revenue Proportion by Application in 2024
Table 67. UCB Revenue Proportion by Geographic Area in 2024
Table 68. UCB Targeted Drugs for Neurodegenerative Diseases SWOT Analysis
Table 69. UCB Recent Developments
Table 70. Sumitomo Pharma Corporation Information
Table 71. Sumitomo Pharma Description and Major Businesses
Table 72. Sumitomo Pharma Product Features and Attributes
Table 73. Sumitomo Pharma Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Sumitomo Pharma Revenue Proportion by Product in 2024
Table 75. Sumitomo Pharma Revenue Proportion by Application in 2024
Table 76. Sumitomo Pharma Revenue Proportion by Geographic Area in 2024
Table 77. Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases SWOT Analysis
Table 78. Sumitomo Pharma Recent Developments
Table 79. Biogen Corporation Information
Table 80. Biogen Description and Major Businesses
Table 81. Biogen Product Features and Attributes
Table 82. Biogen Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Biogen Recent Developments
Table 84. Eisai Inc. Corporation Information
Table 85. Eisai Inc. Description and Major Businesses
Table 86. Eisai Inc. Product Features and Attributes
Table 87. Eisai Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Eisai Inc. Recent Developments
Table 89. Eli Lilly Corporation Information
Table 90. Eli Lilly Description and Major Businesses
Table 91. Eli Lilly Product Features and Attributes
Table 92. Eli Lilly Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Eli Lilly Recent Developments
Table 94. Green Valley Corporation Information
Table 95. Green Valley Description and Major Businesses
Table 96. Green Valley Product Features and Attributes
Table 97. Green Valley Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Green Valley Recent Developments
Table 99. NOVARTIS Corporation Information
Table 100. NOVARTIS Description and Major Businesses
Table 101. NOVARTIS Product Features and Attributes
Table 102. NOVARTIS Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. NOVARTIS Recent Developments
Table 104. Bristol-Myers Squibb Corporation Information
Table 105. Bristol-Myers Squibb Description and Major Businesses
Table 106. Bristol-Myers Squibb Product Features and Attributes
Table 107. Bristol-Myers Squibb Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Bristol-Myers Squibb Recent Developments
Table 109. Janssen Corporation Information
Table 110. Janssen Description and Major Businesses
Table 111. Janssen Product Features and Attributes
Table 112. Janssen Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Janssen Recent Developments
Table 114. Sanofi Corporation Information
Table 115. Sanofi Description and Major Businesses
Table 116. Sanofi Product Features and Attributes
Table 117. Sanofi Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. Sanofi Recent Developments
Table 119. Roche Corporation Information
Table 120. Roche Description and Major Businesses
Table 121. Roche Product Features and Attributes
Table 122. Roche Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. Roche Recent Developments
Table 124. Neurocrine Corporation Information
Table 125. Neurocrine Description and Major Businesses
Table 126. Neurocrine Product Features and Attributes
Table 127. Neurocrine Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. Neurocrine Recent Developments
Table 129. Lundbeck Corporation Information
Table 130. Lundbeck Description and Major Businesses
Table 131. Lundbeck Product Features and Attributes
Table 132. Lundbeck Revenue (US$ Million) and Gross Margin (2020-2025)
Table 133. Lundbeck Recent Developments
Table 134. Teva Corporation Information
Table 135. Teva Description and Major Businesses
Table 136. Teva Product Features and Attributes
Table 137. Teva Revenue (US$ Million) and Gross Margin (2020-2025)
Table 138. Teva Recent Developments
Table 139. Raw Materials Key Suppliers
Table 140. Distributors List
Table 141. Market Trends and Market Evolution
Table 142. Market Drivers and Opportunities
Table 143. Market Challenges, Risks, and Restraints
Table 144. Research Programs/Design for This Report
Table 145. Key Data Information from Secondary Sources
Table 146. Key Data Information from Primary Sources
List of Figures
Figure 1. Targeted Drugs for Neurodegenerative Diseases Product Picture
Figure 2. Global Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Injection Product Picture
Figure 4. Oral Product Picture
Figure 5. Global Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Parkinson's Disease (PD)
Figure 7. Alzheimer's Disease (AD)
Figure 8. Huntington's Disease (HD)
Figure 9. Tardive Dyskinesia (TD)
Figure 10. Multiple Sclerosis (MS)
Figure 11. Targeted Drugs for Neurodegenerative Diseases Report Years Considered
Figure 12. Global Targeted Drugs for Neurodegenerative Diseases Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 14. Global Targeted Drugs for Neurodegenerative Diseases Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Region (2020-2031)
Figure 16. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share Ranking (2024)
Figure 17. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 18. Injection Revenue Market Share by Player in 2024
Figure 19. Oral Revenue Market Share by Player in 2024
Figure 20. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Type (2020-2031)
Figure 21. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Application (2020-2031)
Figure 22. North America Targeted Drugs for Neurodegenerative Diseases Revenue YoY (2020-2031) & (US$ Million)
Figure 23. North America Top 5 Players Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) in 2024
Figure 24. North America Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) by Type (2020 - 2031)
Figure 25. North America Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) by Application (2020-2031)
Figure 26. US Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 27. Canada Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 28. Mexico Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 29. Europe Targeted Drugs for Neurodegenerative Diseases Revenue YoY (2020-2031) & (US$ Million)
Figure 30. Europe Top 5 Players Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) in 2024
Figure 31. Europe Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) by Type (2020-2031)
Figure 32. Europe Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) by Application (2020-2031)
Figure 33. Germany Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 34. France Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 35. U.K. Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 36. Italy Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 37. Russia Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 38. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Revenue YoY (2020-2031) & (US$ Million)
Figure 39. Asia-Pacific Top 8 Players Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) in 2024
Figure 40. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) by Type (2020-2031)
Figure 41. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) by Application (2020-2031)
Figure 42. Indonesia Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 43. Japan Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 44. South Korea Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 45. Australia Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 46. India Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 47. Indonesia Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 48. Vietnam Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 49. Malaysia Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 50. Philippines Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 51. Singapore Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2031) & (US$ Million)
Figure 52. Central and South America Targeted Drugs for Neurodegenerative Diseases Revenue YoY (2020-2031) & (US$ Million)
Figure 53. Central and South America Top 5 Players Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) in 2024
Figure 54. Central and South America Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) by Type (2020-2031)
Figure 55. Central and South America Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) by Application (2020-2031)
Figure 56. Brazil Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2025) & (US$ Million)
Figure 57. Argentina Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2025) & (US$ Million)
Figure 58. Middle East and Africa Targeted Drugs for Neurodegenerative Diseases Revenue YoY (2020-2031) & (US$ Million)
Figure 59. Middle East and Africa Top 5 Players Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) in 2024
Figure 60. South America Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) by Type (2020-2031)
Figure 61. Middle East and Africa Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) by Application (2020-2031)
Figure 62. GCC Countries Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2025) & (US$ Million)
Figure 63. Israel Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2025) & (US$ Million)
Figure 64. Egypt Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2025) & (US$ Million)
Figure 65. South Africa Targeted Drugs for Neurodegenerative Diseases Revenue (2020-2025) & (US$ Million)
Figure 66. Targeted Drugs for Neurodegenerative Diseases Industry Chain Mapping
Figure 67. Channels of Distribution (Direct Vs Distribution)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global UV Delayed Curing Adhesives Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Global Die-Casting Die Steel Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Global Adaptive Neuromodulation Therapy Devices Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232